Cerenome (CNSY) vs Karyopharm Therapeutics (KPTI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cerenome (CNSY) has outperformed Karyopharm Therapeutics (KPTI) over the past year, losing 89.3% versus a loss of 89.6%. Over five years, KPTI leads with a -99.3% price change compared with -99.7% for CNSY. Cerenome is the larger company by market cap ($14.6 million vs $13.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNSY | KPTI |
|---|---|---|
| Share price | $1.93 | $0.605 |
| Market cap | $14.65M | $13.72M |
| 1-day change | +7.82% | +0.83% |
| YTD return | -84.86% | -91.78% |
| 1-year return | -89.28% | -89.60% |
| 5-year return | -99.73% | -99.28% |
| EPS (TTM) | $-3.36 | $-14.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.00 | $10.99 |
| 52-week low | $1.49 | $0.5652 |
| Distance from 52-week high | -89.84% | -94.49% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +1337.82% | +1098.35% |
| Average volume | 121.12K | 1.71M |
| Shares outstanding | 7.59M | 22.68M |
| Employees | 28 | 228 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Cerenome
CNSY stock →Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
Health Care · Medical/Dental Instruments · 28 employees
About Karyopharm Therapeutics
KPTI stock →Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).
Health Care · Biotechnology: Pharmaceutical Preparations · 228 employees
CNSY vs KPTI FAQ
Which is bigger, Cerenome or Karyopharm Therapeutics?
Cerenome (CNSY) is larger, with a market capitalization of $14.65M compared with $13.72M for Karyopharm Therapeutics (KPTI).
Which stock has performed better over the past year, CNSY or KPTI?
CNSY returned -89.28% over the past 12 months, compared with -89.60% for KPTI (price return, excluding dividends). Past performance does not predict future results.
Are Cerenome and Karyopharm Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for Cerenome and Biotechnology: Pharmaceutical Preparations for Karyopharm Therapeutics.